WCG Clinical, Inc.
| General Information | |
| Business: | (Note: WCG Clinical, Inc., withdrew its IPO in a letter dated Oct. 13, 2021, to the SEC. WCG Clinical had postponed its IPO on Aug. 5, 2021, the day that its stock was expected to start trading on the NASDAQ.) We believe we are a leading provider of clinical trial solutions, focused on providing solutions that are designed to measurably improve the quality and efficiency of clinical research, stimulate growth and foster compliance. Our transformational solutions enable biopharmaceutical companies, contract research organizations (“CROs”), and institutions to accelerate the delivery of new treatments and therapies to patients, while maintaining the highest standards of human protection. We leverage our differentiated strategic position at the center of the clinical trial ecosystem to provide new types of technology-enabled solutions to all stakeholders involved, with the aim to address the key critical pain points throughout the clinical trial process. WCG was founded in 2012, backed by Arsenal Capital Partners, with the goal of systematically transforming drug development by addressing the key critical pain points adversely affecting clinical trial performance. Our proprietary suite of technology-enabled solutions provides ethical review services as well as broader clinical trial solutions, including study planning and optimization, patient engagement and scientific and regulatory review services.
Our management estimates that over the last two years ended Dec.31, 2020, WCG supported approximately 90% of all global clinical trials, across a broad array of therapeutic areas and trial phases and, over the same period, our solutions have been leveraged by 87% of all new drugs and therapeutic biologics approved by the U.S. Food and Drug Administration (“FDA”). With a global workforce of over 4,000 individuals who are core to our mission and our platform, we have a presence in 71 countries. Our significant expertise is evidenced by our track record of supporting over 4,000 global clinical trials from March 2020 through February 2021.
|
| Industry: | Services - Commercial Physical & Biological Research |
| Employees: | 4400 |
| Founded: | 2012 |
| Contact Information | |
| Address | 212 Carnegie Center, Suite 301 Princeton, NJ 08540 |
| Phone Number | (609) 945-0101 |
| Web Address | http://www.wcgclinical.com/ |
| View Prospectus: | WCG Clinical, Inc. |
| Financial Information | |
| Market Cap | $6067.04mil |
| Revenues | $497.5 mil (last 12 months) |
| Net Income | $-85.8 mil (last 12 months) |
| IPO Profile | |
| Symbol | WCGC |
| Exchange | NASDAQ |
| Shares (millions): | 45.0 |
| Price range | $15.00 - $17.00 |
| Est. $ Volume | $720.0 mil |
| Manager / Joint Managers | Goldman Sachs/ Morgan Stanley/ BofA Securities/ Barclays/ Jefferies/ William Blair/ BMO Capital Markets/ UBS Investment Bank/ SVB Leerink/ HSBC |
| CO-Managers | - |
| Expected To Trade: | 8/5/2021 |
| Status: | Withdrawn |
| Quiet Period Expiration Date: | Available only to Subscribers |
| Lock-Up Period Expiration Date: | Available only to Subscribers |
| SCOOP Rating | Available only to Subscribers |
| Rating Change | Available only to Subscribers |